Literature DB >> 12532323

Prospects for cannabinoids as anti-inflammatory agents.

Robert B Zurier1.   

Abstract

The marijuana plant (Cannabis sativa) and preparations derived from it have been used for medicinal purposes for thousands of years. It is likely that the therapeutic benefits of smoked marijuana are due to some combination of its more than 60 cannabinoids and 200-250 non-cannabinoid constituents. Several marijuana constituents, the carboxylic acid metabolites of tetrahydrocannabinol, and synthetic analogs are free of cannabimimetic central nervous system activity, do not produce behavioral changes in humans, and are effective antiinflammatory and analgesic agents. One cannabinoid acid in particular, ajulemic acid, has been studied extensively in in vitro systems and animal models of inflammation and immune responses. This commentary reviews a portion of the work done by investigators interested in separating the medicinal properties of marijuana from its psychoactive effects. Understanding the mechanisms of the therapeutic effects of nonpsychoactive cannabinoids should lead to development of safe effective treatment for several diseases, and may render moot the debate about "medical marijuana". Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532323     DOI: 10.1002/jcb.10291

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  20 in total

1.  HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid.

Authors:  Christeene G Haj; Percy F Sumariwalla; Lumír Hanuš; Natalya M Kogan; Zhana Yektin; Raphael Mechoulam; Mark Feldmann; Ruth Gallily
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

Review 2.  Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Authors:  William E Greineisen; Helen Turner
Journal:  Int Immunopharmacol       Date:  2010-02-25       Impact factor: 4.932

3.  Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis.

Authors:  Udai P Singh; Narendra P Singh; Balwan Singh; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Toxicol Appl Pharmacol       Date:  2011-11-18       Impact factor: 4.219

4.  Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

Authors:  Gerald T DeLong; Carl E Wolf; Alphonse Poklis; Aron H Lichtman
Journal:  Drug Alcohol Depend       Date:  2010-11-01       Impact factor: 4.492

5.  Potential anti-inflammatory actions of the elmiric (lipoamino) acids.

Authors:  Sumner H Burstein; Jeffrey K Adams; Heather B Bradshaw; Cristian Fraioli; Ronald G Rossetti; Rebecca A Salmonsen; John W Shaw; J Michael Walker; Robert E Zipkin; Robert B Zurier
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

6.  The endogenous cannabinoid system protects against colonic inflammation.

Authors:  Federico Massa; Giovanni Marsicano; Heike Hermann; Astrid Cannich; Krisztina Monory; Benjamin F Cravatt; Gian-Luca Ferri; Andrei Sibaev; Martin Storr; Beat Lutz
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 7.  Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Authors:  Joep Killestein; Bernard M J Uitdehaag; Chris H Polman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis.

Authors:  B Romano; F Borrelli; I Fasolino; R Capasso; F Piscitelli; Mg Cascio; Rg Pertwee; D Coppola; L Vassallo; P Orlando; V Di Marzo; Aa Izzo
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 9.  Cannabinoids and glaucoma.

Authors:  I Tomida; R G Pertwee; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

10.  Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4.

Authors:  Robert B Zurier; Yee-Ping Sun; Kerri L George; Judith A Stebulis; Ronald G Rossetti; Ann Skulas; Erica Judge; Charles N Serhan
Journal:  FASEB J       Date:  2009-01-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.